PRESS RELEASE published on 03/10/2023 at 17:00, 3 years 5 months ago Moderna Outlines Commitment to Corporate Growth and Announces U.S. Expansion in 2023
PRESS RELEASE published on 02/28/2023 at 13:30, 3 years 5 months ago Moderna to Present at Cowen's 43rd Annual Health Care Conference
PRESS RELEASE published on 02/23/2023 at 13:00, 3 years 5 months ago Moderna Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Updates
PRESS RELEASE published on 02/22/2023 at 22:05, 3 years 5 months ago Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA(R) (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients With High-Risk Mela
PRESS RELEASE published on 02/22/2023 at 13:00, 3 years 5 months ago Moderna And Life Edit Therapeutics Enter Strategic Collaboration to Accelerate the Development of Novel In Vivo Gene Editing Therapies
PRESS RELEASE published on 02/17/2023 at 17:00, 3 years 5 months ago Health Canada Authorizes Moderna's Omicron-Targeting Bivalent COVID-19 Vaccine in Children & Adolescents (6-17 Years)
PRESS RELEASE published on 02/16/2023 at 22:05, 3 years 5 months ago Moderna Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, a Seasonal Influenza Vaccine Candidate
PRESS RELEASE published on 02/02/2023 at 13:00, 3 years 6 months ago Moderna to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 23, 2023
PRESS RELEASE published on 01/30/2023 at 13:15, 3 years 6 months ago Moderna Granted FDA Breakthrough Therapy Designation for mRNA-1345, An Investigational Respiratory Syncytial Virus (RSV) Vaccine Candidate
PRESS RELEASE published on 01/17/2023 at 22:05, 3 years 6 months ago Moderna Announces mRNA-1345, an Investigational Respiratory Syncytial Virus (RSV) Vaccine, Has Met Primary Efficacy Endpoints in Phase 3 Trial in Older Adults
Published on 08/15/2026 at 00:50, 10 hours 12 minutes ago Revive Therapeutics Reports Grant of Options
Published on 08/15/2026 at 00:15, 10 hours 47 minutes ago Full Circle Lithium Announces Closing of Private Placement
Published on 08/14/2026 at 23:45, 11 hours 17 minutes ago AI/ML Innovations Inc. Announces Proposed Private Placement
Published on 08/14/2026 at 23:25, 11 hours 37 minutes ago NuRAN Wireless Closes $7.6 Million Financing
Published on 08/14/2026 at 23:00, 12 hours 2 minutes ago Medicure Reports Financial Results for Quarter Ended June 30, 2026 and Schedules August 17, 2026 Conference Call
Published on 08/15/2026 at 08:05, 2 hours 56 minutes ago SKYWORTH Solar to Launch SolaMate Balcony Solar System on Joybuy Germany on August 15
Published on 08/14/2026 at 18:15, 16 hours 47 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 08/14/2026 at 16:05, 18 hours 56 minutes ago GATORADE WELCOMES AITANA BONMATÍ TO TEAM GATORADE AHEAD OF THE NEW FOOTBALL SEASON
Published on 08/14/2026 at 15:29, 19 hours 32 minutes ago Tradegate AG publishes its half-year report
Published on 08/10/2026 at 18:00, 4 days 17 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 11:53, 4 days 23 hours ago GUILLEMOT CORPORATION | Information regarding the total number of voting rights and shares 31/07/2026
Published on 08/10/2026 at 11:36, 4 days 23 hours ago GUILLEMOT CORPORATION| Weekly report share buyback from August 3 to August 7 2026
Published on 08/10/2026 at 09:22, 5 days 1 hour ago Number of shares and voting rights - July 2026 (In French only)
